Amazon.com Inc (NASDAQ:AMZN)’s insertion of video ads into Prime Video content will unlock substantial revenue at high incremental margins, bolstering the margin bull case, according to UBS analysts.
In an update to clients, they raised their target price on Amazon stock from $175 to $180 per share, while maintaining their ‘Buy’ rating, noting the move looks well timed given inflecting budget shifting to Connected TV (CTV) amidst cord cutting.
Demand for Apple Inc (NASDAQ:AAPL)'s iPhone 15 is already dropping off in China, signaling a potential decrease in consumer interest in the most recent version of the iPhone 15.
Analysts at Jefferies noted that resale prices of the iPhone 15 Pro Max (15PM) have dropped up to 17% in Hong Kong.
NVIDIA Corp shares rose nearly 3% to $446.09 in midday trading on Monday after Goldman Sachs analysts added the semiconductor manufacturer to the bank's 'Americas Conviction List', an upgrade from its previous 'Buy' rating, while maintaining their $605 per share target price on the stock.
"Look for Nvidia to maintain its statues as the accelerated computing industry standard for the foreseeable futures given its competitive moat and the urgency with which customers are developing and deploying increasingly complex AI models," the analysts wrote.
Tesla Inc (NASDAQ:TSLA) is set to be enter its next stage of growth, that’s according to analysts at Wedbush who shrug off Monday’s disappointing delivery numbers that fell short of Wall Street expectations.
Elon Musk’s EV stock fell more than 2.5% in early deals but had rallied back to parity within the first hour of trading.
Analysts at UBS have readjusted their guidance on Ladbrokes and Coral-owner Entain PLC (LSE:ENT) following last week’s tepid trading update.
In that update, Entain warned online gaming revenue has been softer than expected, hit by adverse sporting results during September and ongoing regulatory headwinds.
Moonpig were a strong performer after 2.5% to 167.3p after positive comments from Jefferies.
The bank reiterated a buy rating after the online greeting card retailer’s recent solid AGM statement and after it hosted an upbeat ‘fireside chat.”
By raising its stake in Aston Martin to 26.2%, the Yew Tree consortium underlined its confidence in the luxury car group's turnaround but breached a standstill agreement with Geely, another major shareholder, says broker Jefferies.
Yew Tree had agreed with the Chinese car group not to exceed 25% until at least August 2024.
Crude oil prices to slump to as low as US$70 a barrel next year due to sluggish demand and as “peak transport fuel demand” looms, according to US bank Citigroup.
Prices have been rising steadily (to US$92 currently) since the middle of the year as key producers Saudi Arabia and Russia have cut production.
Quadrise shares are close to an all-time low, despite assurances that a ruling in Utah would not materially impact its development plan with Valkor, notes house broker Shore Capital.
Also, Quadrise intends to conclude agreements with stakeholders of its project with MSC Shipmanagement, including a major global trading company, as soon as possible, following the completion of key preparatory steps for the commercial trials of bioMSAR.
Flutter Entertainment PLC (LSE:FLTR) shares were trading sideways - with the UK investors seemingly unaware of the bumper weekend of sports betting in the US.
According to Jefferies, the online market is maintaining what looks to be year-on-year growth of around 30%.
Citi has upgraded its rating for Antofagasta PLC (LSE:ANTO) to 'buy' based on the Chile-focused FTSE 100 miner's potential for volume recovery and compelling valuation.
The upgrade comes as Antofagasta is expected to see a significant recovery in copper production, adding 26% to its estimated underlying earnings (EBITDA) over the next two years.
Futura Medical PLC (AIM:FUM, OTC:FAMDF), a pharmaceutical company specialising in sexual health products, has witnessed a 3% increase in its share price after securing a pivotal patent from the European Patent Office for MED3000, its erectile dysfunction (ED) gel.
The patent, which covers the product commercially known as Eroxon, extends protection across all European markets until the year 2040.